Filtered By:
Cancer: Lung Cancer
Management: Hospitals
This page shows you your search results in order of date.
Order by Relevance | Date
Total 589 results found since Jan 2013.
Long-course chemoradiation plus concurrent/sequential PD-1 blockade as neoadjuvant treatment for MMR-status-unscreened locally advanced rectal cancer: protocol of a multicentre, phase 2, randomised controlled trial (the POLAR-STAR trial)
BMJ Open. 2023 Sep 12;13(9):e069499. doi: 10.1136/bmjopen-2022-069499.ABSTRACTINTRODUCTION: Recent preclinical studies have discovered unique synergism between radiotherapy and immune checkpoint inhibitors, which has already brought significant survival benefit in lung cancer. In locally advanced rectal cancer (LARC), neoadjuvant radiotherapy plus immune checkpoint inhibitors have also achieved surprisingly high pathological complete response (pCR) rates even in proficient mismatch-repair patients. As existing researches are all phase 2, single-cohort trials, we aim to conduct a randomised, controlled trial to further clar...
Source: Cancer Control - September 12, 2023 Category: Cancer & Oncology Authors: Kai Pang Yun Yang Dan Tian Na Zeng Shun Cao Shen Ling Jiale Gao Pengfei Zhao Hao Wang Yuanyuan Kong Jie Zhang Guangyong Chen Wei Deng Zhigang Bai Lan Jin Guoju Wu Danyang Zhu Yue Wang Jiaolin Zhou Bin Wu Guole Lin Yi Xiao Zhidong Gao Yingjiang Ye Xin Wang Source Type: research
Early mortality in German patients with lung cancer: risk factors associated with 30-and 60-day mortality
In this study, we aimed to assess risk factors for 30- and 60-day mortality in German lung cancer patients. In this retrospective cross-sectional analysis, we used data of lung cancer patients treated at LMU Hospital Munich between 2015 and 2019. We categorized patients into 30-day mortality, 60 day-mortality, and longer survival. We used Student's t-test and ANOVA to compare means and Chi2-test to compare frequencies. We used logistic regression analysis to identify factors associated with a risk for early mortality. Of the 2454 lung cancer patients, 2.0% (n = 50) died within 30 and 1.7% (n = 41) within 30 to 60 days of d...
Source: Clinical Lung Cancer - September 12, 2023 Category: Cancer & Oncology Authors: Amanda Tufman Sophie Schneiderbauer Julia Walter Blerina Resuli Diego Kauffmann-Guerrero Carlo M ümmler Pontus Mertsch Jeremias G ötschke Julia Kov ács Farkhad Manapov Christian Schneider Laura Sellmer Paola Arnold Volker Heinemann J ürgen Behr Daniel Source Type: research
Maintenance anlotinib improves the survival prognosis of extensive-stage small cell lung cancer: a single-arm, prospective, phase II study
Am J Cancer Res. 2023 Aug 15;13(8):3679-3685. eCollection 2023.ABSTRACTThe extent to which anlotinib provides survival benefits in the maintenance therapy of extensive-stage small cell lung cancer (ES-SCLC) remains unclear. Thus, this study aimed to assess the efficacy and safety of anlotinib monotherapy as maintenance therapy following induction chemotherapy in ES-SCLC patients. 27 ES-SCLC patients registered at the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine were screened from February 2022 to October 2022, of which 3 were not eligible. Eligible patients in stable status after first-line...
Source: Cell Research - September 11, 2023 Category: Cytology Authors: Fanming Kong Ziwei Wang Na Wang Dou Zhang Dongying Liao Jing Zhang Yidan Sun Haojian Zhang Yingjie Jia Source Type: research
Clinical outcome analysis of non-small cell lung cancer patients with brain metastasis receiving metastatic brain tumor resection surgery: a multicenter observational study
Am J Cancer Res. 2023 Aug 15;13(8):3607-3617. eCollection 2023.ABSTRACTBrain metastasis is most common in primary non-small cell lung cancer (NSCLC), and some patients require neurosurgical resection for intracranial disease control. Because advances in systemic therapies for metastatic NSCLC have been developed in the past decade, we aimed to analyze and determine clinical factors associated with the postresection survival of NSCLC patients with brain metastasis who underwent neurosurgery followed by systemic therapy. Between January 2017 and December 2021, data for 93 NSCLC patients with brain metastasis treated with neu...
Source: Cell Research - September 11, 2023 Category: Cytology Authors: Ping-Chih Hsu Li-Chung Chiu Ko-Ting Chen Chun-Chieh Wang Chen-Te Wu Chiao-En Wu Ho-Wen Ko Scott Chih-Hsi Kuo Yu-Ching Lin Chin-Chou Wang Cheng-Ta Yang Source Type: research
Efficacy of gefapixant, a P2X < sub > 3 < /sub > antagonist, for lung cancer-related cough: a case report
We report the case of a woman in her late 70s who never smoked and had advanced lung cancer. She visited our hospital complaining of serious deterioration of a non-productive cough. She was diagnosed with relapse of lung cancer, but she requested 2-week anti-tussive therapy before second-line chemotherapy. Gefapixant (P2X3 antagonist) add-on at a dose of 90 mg/day (45 mg twice daily as the usual dosage in Japan) improved her cough as indicated by an improvement in the visual analog scale for cough from 70 to 20 mm and in the Japanese version of the Leicester Cough Questionnaire from 8.2 to 16.3, despite a deterioration in ...
Source: Cancer Control - August 29, 2023 Category: Cancer & Oncology Authors: Yoshihisa Ishiura Shosaku Nomura Yuka Ishii Kai Imai Yusuke Sawai Takeshi Tamaki Toshiki Shimizu Naoyuki Miyashita Tomoki Ito Source Type: research
Predictors of Length of Stay, Mortality and Rehospitalization in COPD Patients: A Retrospective Cohort Study
This study aimed to identify factors that predict the length of a hospital stay (LOHS), one-year mortality, and rehospitalization within 6 months in patients admitted for acute exacerbation of COPD (AECOPD). A retrospective cohort study was conducted using data from 170 patients admitted to a district general hospital in Switzerland between January 2019 and February 2020. Sociodemographic and health-related variables measured at admission were analyzed as potential predictors. Multivariable zero-truncated negative binomial and logistic regression analyses were performed to assess the risk factors for LOHS (primary endpoint...
Source: Clinical Lung Cancer - August 26, 2023 Category: Cancer & Oncology Authors: Giorgia L üthi-Corridori Maria Boesing Nicola Ottensarendt Anne Barbara Leuppi-Taegtmeyer Philipp Schuetz Joerg Daniel Leuppi Source Type: research
An overview on the relationship between residential radon and lung cancer: what we know and future research
Clin Transl Oncol. 2023 Aug 23. doi: 10.1007/s12094-023-03308-0. Online ahead of print.ABSTRACTWe aim to provide an overview of the research available on indoor radon and lung cancer, with a special focus on Spanish investigations. Early studies on underground miners established the link between radon and lung cancer, which was later confirmed for the general population by residential case-control studies. Spain contributed with extensive evidence, including 5 multicentric, hospital-based, case-control studies in the last 30 years, exploring diverse aspects, such as radon's effect on never-smokers, molecular pathways linki...
Source: Clinical Lung Cancer - August 23, 2023 Category: Cancer & Oncology Authors: Alberto Ruano-Ravina Lucia Martin-Gisbert Karl Kelsey M ónica Pérez-Ríos Cristina Candal-Pedreira Julia Rey-Brandariz Leonor Varela-Lema Source Type: research
Potential causal links of long-term air pollution with lung cancer incidence: From the perspectives of mortality and hospital admission in a large cohort study in southern China
We examined the relationship between lung cancer and long-term exposure to particulate matter (PM, including PM2.5 , PM10 and PM10-2.5 ) and nitrogen dioxide (NO2 ) among a large cohort of general Chinese adults using causal inference approaches. The study included 575 592 participants who were followed up for an average of 8.2 years. The yearly exposure of PM and NO2 was estimated through satellite-based random forest approaches and the ordinary kriging method, respectively. Marginal structural Cox models were used to examine hazard ratios (HRs) of mortality and hospital admission due to lung cancer following air pollutio...
Source: Cancer Control - August 23, 2023 Category: Cancer & Oncology Authors: Tong Guo Shirui Chen Ying Wang Yuqin Zhang Zhicheng Du Wenjing Wu Shimin Chen Xu Ju Zhiqiang Li Qinlong Jing Yuantao Hao Wangjian Zhang Source Type: research
An overview on the relationship between residential radon and lung cancer: what we know and future research
Clin Transl Oncol. 2023 Aug 23. doi: 10.1007/s12094-023-03308-0. Online ahead of print.ABSTRACTWe aim to provide an overview of the research available on indoor radon and lung cancer, with a special focus on Spanish investigations. Early studies on underground miners established the link between radon and lung cancer, which was later confirmed for the general population by residential case-control studies. Spain contributed with extensive evidence, including 5 multicentric, hospital-based, case-control studies in the last 30 years, exploring diverse aspects, such as radon's effect on never-smokers, molecular pathways linki...
Source: Cancer Control - August 23, 2023 Category: Cancer & Oncology Authors: Alberto Ruano-Ravina Lucia Martin-Gisbert Karl Kelsey M ónica Pérez-Ríos Cristina Candal-Pedreira Julia Rey-Brandariz Leonor Varela-Lema Source Type: research
TRIM11 promotes cell proliferation of non-small cell lung cancer through the inhibition of ferroptosis by AMPK
This study investigates the role of TRIM11 gene in NSCLC and its underlying mechanism. NSCLC patients were recruited from our hospital and showed upregulated TRIM11 mRNA and protein expressions. Patients with high TRIM11 expression had lower survival rates. TRIM11 gene was found to promote cell proliferation and reduce ROS-induced ferroptosis in NSCLC. Additionally, TRIM11 gene induced AMPK expression and its regulation affected TRIM11's effects on cell proliferation and ferroptosis in NSCLC. IP analysis revealed that TRIM11 protein interacted with AMPK protein in NSCLC. These data confirmed that TRIM11 promotes cell proli...
Source: Clinical Lung Cancer - August 21, 2023 Category: Cancer & Oncology Authors: Zheng Liang Jian Li Guoliang Zhang Menghui Chen Source Type: research
Serratus anterior plane block as a successful single anesthesia technique for thoracoscopy biopsy surgery: A case series
We report three cases of suspected lung cancer patients who underwent thoracoscopic biopsy and postoperative chest drainage. The patients underwent SAPB with light sedation during the procedure. After surgery, the patients were observed in the intensive care unit. For postoperative pain management, nonsteroidal anti-inflammatory drugs (NSAIDs) were used as an adjunct to intraoperative SAPB. Adequate pain control was achieved on a numeric rating scale of 0 to 2 over the 1 × 24 postoperative period, and opioid analgesics were not used in these patients. SAPB was successfully used in patients undergoing thoracoscopy biopsy s...
Source: Cancer Control - August 21, 2023 Category: Cancer & Oncology Authors: Ruddi Hartono None Isngadi Andreas Willianto Djudjuk Rahmad Basuki Aswoco Andyk Asmoro Ahmad Feza Fadhlurrahman Source Type: research
Ultrasound-guided pleural biopsy following a non-diagnostic thoracentesis for non-small cell lung cancer
We report a case of a 65-year-old man with a cavitary lung mass and parietal-based pleural nodules in which a pleural ultrasound-guided approach yielded a definitive diagnosis of stage IV non-small cell lung carcinoma. Computed tomography-guided biopsy is often preferred approach for the majority of United States hospitals for sampling pleural nodules as compared to US. The advantages of an US-guided approach include [1]: increased portability [2]; decreased procedure time [3]; reduced reliance on dedicated ancillary support staff [4]; need for local anesthesia only [5]; lack of ionizing radiation exposure; and [6] cost re...
Source: Respiratory Care - August 16, 2023 Category: Respiratory Medicine Authors: William McManigle Brad Petkovich Harrison Smith Amit Chopra John T Huggins Source Type: research
